Furth Noa, Shilo Shay, Cohen Niv, Erez Nir, Fedyuk Vadim, Schrager Alexander M, Weinberger Adina, Dror Amiel A, Zigron Asaf, Shehadeh Mona, Sela Eyal, Srouji Samer, Amit Sharon, Levy Itzchak, Segal Eran, Dahan Rony, Jones Dan, Douek Daniel C, Shema Efrat
Department of Biological Regulation, Weizmann Institute of Science, Rehovot, Israel.
Human Immunology Section, Vaccine Research Center, National Institutes of Health, Bethesda, MD, USA.
medRxiv. 2021 Jul 27:2021.05.25.21257501. doi: 10.1101/2021.05.25.21257501.
The COVID-19 pandemic raises the need for diverse diagnostic approaches to rapidly detect different stages of viral infection. The flexible and quantitative nature of single-molecule imaging technology renders it optimal for development of new diagnostic tools. Here we present a proof-of-concept for a single-molecule based, enzyme-free assay for detection of SARS-CoV-2. The unified platform we developed allows direct detection of the viral genetic material from patients' samples, as well as their immune response consisting of IgG and IgM antibodies. Thus, it establishes a platform for diagnostics of COVID-19, which could also be adjusted to diagnose additional pathogens.
新冠疫情凸显了对多种诊断方法的需求，以便快速检测病毒感染的不同阶段。单分子成像技术具有灵活性和定量性，使其成为开发新诊断工具的理想选择。在此，我们展示了一种基于单分子、无酶检测严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的概念验证。我们开发的统一平台能够直接检测患者样本中的病毒遗传物质，以及由IgG和IgM抗体组成的免疫反应。因此，它建立了一个用于诊断新冠的平台，该平台也可进行调整以诊断其他病原体。
